Aethlon Medical (NasdaqCM: AEMD) to Ring the Nasdaq
Stock Market Closing Bell on July 24th
SAN DIEGO - July 21, 2015 (Investorideas.com
newswire) Aethlon Medical, Inc. (NasdaqCM:AEMD),
the pioneer in creating affinity biofiltration devices to treat
life-threatening diseases, today announced that the Company will ring the
Nasdaq Stock Market closing bell on Friday, July 24, 2015 in honor of its
recent listing on the Nasdaq Capital Market. Attending the event on behalf of
Aethlon Medical will be Jim Joyce, Chairman and Chief Executive Officer and Jim
Frakes, Chief Financial Officer.
"Ringing
the closing bell marks an exciting time for our Company both in regards to our
recent Nasdaq listing and the opportunities for our Aethlon Hemopurifier® to
play a critical role in the elimination of infectious viruses and cancer
promoting exosomes from the circulatory system," stated Jim Joyce,
Chairman and CEO of Aethlon Medical.
The
event will take place at the Nasdaq MarketSite in Times Square on Friday, July
24th from 3:45 p.m. to 4:00 p.m. ET.
About Aethlon Medical, Inc.
Aethlon
Medical creates affinity biofiltration devices to treat life-threatening
diseases. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a
first-in-class device that targets the rapid elimination of infectious viruses
and cancer-promoting exosomes from the circulatory system of treated
individuals. U.S. clinical progression of Hemopurifier therapy is being
advanced under an FDA approved clinical study. We also provide government
contracting services to the Defense Advanced Research Projects Agency related
to the development of a biofiltration device to treat sepsis. Additional
information can be found online at www.AethlonMedical.com or you can connect
with us on on Twitter, LinkedIn, Facebook and Google+.
Certain
statements herein may be forward-looking and involve risks and uncertainties.
Such forward-looking statements involve assumptions, known and unknown risks,
uncertainties and other factors which may cause the actual results, performance
or achievements of Aethlon Medical, Inc. to be materially different from any
future results, performance, or achievements expressed or implied by the
forward-looking statements. Such potential risks and uncertainties include,
without limitation, that the ESI will not be able to commercialize its future
products, that the FDA will not approve the initiation of the Company's
clinical programs or provide market clearance of the company's products, future
human studies whether revenue or non-revenue generating of the Aethlon ADAPT™
system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient
responsiveness to established cancer or hepatitis C therapies or as a
standalone cancer or hepatitis C therapy or as a broad spectrum defense against
viral pathogens, including Ebola, the Company's ability to raise capital when
needed, the Company's ability to complete the development of its planned
products, the Company's ability to manufacture its products either internally
or through outside companies and provide its services, the impact of government
regulations, patent protection on the Company's proprietary technology, the
ability of the Company to meet the milestones contemplated in the DARPA
contract, product liability exposure, uncertainty of market acceptance, competition,
technological change, and other risk factors. In such instances, actual results
could differ materially as a result of a variety of factors, including the
risks associated with the effect of changing economic conditions and other risk
factors detailed in the Company's Securities and Exchange Commission filings.
The Company undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events, or otherwise.
Contacts:
David
Zazoff
MDM Worldwide Solutions
646-403-3554
MDM Worldwide Solutions
646-403-3554
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: The Investorideas.com newswire is a third party
publisher of news and research as well as creates original content as a news
source. Original content created by investorideas is protected by copyright
laws other than syndication rights. Investorideas is a news source on Google
news and Linkedintoday plus hundreds of syndication partners. Our site does not
make recommendations for purchases or sale of stocks or products. Nothing on
our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated by featured companies, news
submissions, content marketing and online advertising. Contact each company
directly for press release questions. Disclosure is posted on each release if
required but otherwise the news was not compensated for and is published for
the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure:
AEMD subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
